{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T07:07:29Z","timestamp":1790665649979,"version":"4.1.0"},"reference-count":75,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2020,8,15]],"date-time":"2020-08-15T00:00:00Z","timestamp":1597449600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,8,15]],"date-time":"2020-08-15T00:00:00Z","timestamp":1597449600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Oncol Rep"],"published-print":{"date-parts":[[2020,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose of Review<\/jats:title>\n                <jats:p>Cancer remains a major cause of morbidity and mortality in HIV-infected individuals, with aggressive non-Hodgkin\u2019s lymphoma as the most frequent one. However, the introduction of modern antiretroviral therapy (ART) drastically improved treatment options and prognosis in HIV-associated lymphomas. This review summarized the current treatment landscape and future challenges in HIV-positive patients with non-Hodgkin\u2019s and Hodgkin\u2019s lymphoma.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Recent Findings<\/jats:title>\n                <jats:p>Selecting the appropriate therapy for the individual patient, diffuse-large B cell lymphoma, Burkitt\u2019s lymphoma, and Hodgkin\u2019s disease may be curable diseases. In contrast, the prognosis of plasmablastic lymphoma and primary effusion lymphoma remain poor. New treatment approaches, as targeted therapies or CAR T cell therapy, may broaden the therapeutic armamentarium.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Summary<\/jats:title>\n                <jats:p>The continuous application of ART is mandatory for successful treatment. The choice of lymphoma therapy may follow the recommendations for HIV-negative patients, but prospective trials in HIV-lymphoma are needed.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s11912-020-00973-0","type":"journal-article","created":{"date-parts":[[2020,8,15]],"date-time":"2020-08-15T07:02:27Z","timestamp":1597474947000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["The Changing Landscape of Lymphoma Associated with HIV Infection"],"prefix":"10.1007","volume":"22","author":[{"given":"Kai","family":"H\u00fcbel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,8,15]]},"reference":[{"issue":"8","key":"973_CR1","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1097\/QAD.0000000000000222","volume":"28","author":"P Morlat","year":"2014","unstructured":"Morlat P, Roussillon C, Henard S, Salmon D, Bonnet F, Cacoub P, et al. Causes of death among HIV-infected patients in France in 2010 (national survey): trends since 2000. AIDS. 2014;28(8):1181\u201391.","journal-title":"AIDS"},{"issue":"RR-10","key":"973_CR2","first-page":"1","volume":"57","author":"E Schneider","year":"2008","unstructured":"Schneider E, et al. Revised surveillance case definitions for HIV infection among adults, adolescents, and children aged <18 months and for HIV infection and AIDS among children aged 18 months to <13 years--United States, 2008. MMWR Recomm Rep. 2008;57(RR-10):1\u201312.","journal-title":"MMWR Recomm Rep"},{"issue":"23","key":"973_CR3","doi-asserted-by":"publisher","first-page":"6100","DOI":"10.1182\/blood-2010-08-301531","volume":"117","author":"J Bohlius","year":"2011","unstructured":"Bohlius J, Schmidlin K, Bou\u00e9 F, F\u00e4tkenheuer G, May M, Caro-Murillo AM, et al. HIV-1-related Hodgkin lymphoma in the era of combination antiretroviral therapy: incidence and evolution of CD4(+) T-cell lymphocytes. Blood. 2011;117(23):6100\u20138.","journal-title":"Blood"},{"key":"973_CR4","first-page":"449","volume-title":"Lymphomas associated with HIV infection. In: WHO classification of tumors of haematopoietic and lymphoid tissues","author":"J Said","year":"2017","unstructured":"Said J, et al. In: Swerdlow SH, et al., editors. Lymphomas associated with HIV infection. In: WHO classification of tumors of haematopoietic and lymphoid tissues. 4th ed. Lyon: IARC Press; 2017. p. 449\u201352.","edition":"4"},{"issue":"6","key":"973_CR5","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1182\/blood-2008-09-180315","volume":"113","author":"A Carbone","year":"2009","unstructured":"Carbone A, Cesarman E, Spina M, Gloghini A, Schulz TF. HIV-associated lymphomas and gamma-herpesviruses. Blood. 2009;113(6):1213\u201324.","journal-title":"Blood"},{"key":"973_CR6","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1182\/asheducation-2013.1.382","volume":"2013","author":"RF Little","year":"2013","unstructured":"Little RF, Dunleavy K. Update on the treatment of HIV-associated hematologic malignancies. Hematology Am Soc Hematol Educ Program. 2013;2013:382\u20138.","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"7","key":"973_CR7","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1158\/1055-9965.EPI-11-0037","volume":"20","author":"EC Breen","year":"2011","unstructured":"Breen EC, Hussain SK, Magpantay L, Jacobson LP, Detels R, Rabkin CS, et al. B-cell stimulatory cytokines and markers of immune activation are elevated several years prior to the diagnosis of systemic AIDS-associated non-Hodgkin B-cell lymphoma. Cancer Epidemiol Biomark Prev. 2011;20(7):1303\u201314.","journal-title":"Cancer Epidemiol Biomark Prev"},{"issue":"5","key":"973_CR8","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1200\/JCO.2009.25.1322","volume":"28","author":"O Landgren","year":"2010","unstructured":"Landgren O, Goedert JJ, Rabkin CS, Wilson WH, Dunleavy K, Kyle RA, et al. Circulating serum free light chains as predictive markers of AIDS-related lymphoma. J Clin Oncol. 2010;28(5):773\u20139.","journal-title":"J Clin Oncol"},{"issue":"6","key":"973_CR9","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1002\/ijc.29494","volume":"137","author":"D Martorelli","year":"2015","unstructured":"Martorelli D, Muraro E, Mastorci K, Dal Col J, Fa\u00e8 DA, Furlan C, et al. A natural HIV p17 protein variant up-regulates the LMP-1 EBV oncoprotein and promotes the growth of EBV-infected B-lymphocytes: implications for EBV-driven lymphomagenesis in the HIV setting. Int J Cancer. 2015;137(6):1374\u201385.","journal-title":"Int J Cancer"},{"issue":"8","key":"973_CR10","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.3851\/IMP1462","volume":"14","author":"Collaboration of Observational, H.I.V.E.R.E.S.G","year":"2009","unstructured":"Collaboration of Observational, H.I.V.E.R.E.S.G, et al. Incidence and risk factors of HIV-related non-Hodgkin's lymphoma in the era of combination antiretroviral therapy: a European multicohort study. Antivir Ther. 2009;14(8):1065\u201374.","journal-title":"Antivir Ther"},{"issue":"14","key":"973_CR11","doi-asserted-by":"publisher","first-page":"1957","DOI":"10.1097\/QAD.0b013e3282ed6338","volume":"21","author":"MJ Silverberg","year":"2007","unstructured":"Silverberg MJ, Neuhaus J, Bower M, Gey D, Hatzakis A, Henry K, et al. Risk of cancers during interrupted antiretroviral therapy in the SMART study. AIDS. 2007;21(14):1957\u201363.","journal-title":"AIDS"},{"issue":"19","key":"973_CR12","doi-asserted-by":"publisher","first-page":"3251","DOI":"10.1182\/blood-2013-04-498964","volume":"122","author":"SK Barta","year":"2013","unstructured":"Barta SK, Xue X, Wang D, Tamari R, Lee JY, Mounier N, et al. Treatment factors affecting outcomes in HIV-associated non-Hodgkin lymphomas: a pooled analysis of 1546 patients. Blood. 2013;122(19):3251\u201362.","journal-title":"Blood"},{"issue":"17","key":"973_CR13","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1182\/blood-2018-01-791400","volume":"134","author":"A Noy","year":"2019","unstructured":"Noy A. Optimizing treatment of HIV-associated lymphoma. Blood. 2019;134(17):1385\u201394.","journal-title":"Blood"},{"issue":"11","key":"973_CR14","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.3324\/haematol.2014.111112","volume":"99","author":"SK Barta","year":"2014","unstructured":"Barta SK, Xue X, Wang D, Lee JY, Kaplan LD, Ribera JM, et al. A new prognostic score for AIDS-related lymphomas in the rituximab-era. Haematologica. 2014;99(11):1731\u20137.","journal-title":"Haematologica"},{"issue":"5","key":"973_CR15","doi-asserted-by":"publisher","first-page":"857","DOI":"10.3324\/haematol.2017.180893","volume":"103","author":"P Schommers","year":"2018","unstructured":". Schommers P, et al. Incidence and risk factors for relapses in HIV-associated non-Hodgkin lymphoma as observed in the German HIV-related lymphoma cohort study. Haematologica. 2018;103(5):857\u201364 Important survey on risk factors for patients with HIV-lymphoma.","journal-title":"Haematologica"},{"issue":"5","key":"973_CR16","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1093\/annonc\/mdv036","volume":"26","author":"SK Barta","year":"2015","unstructured":"Barta SK, Samuel MS, Xue X, Wang D, Lee JY, Mounier N, et al. Changes in the influence of lymphoma- and HIV-specific factors on outcomes in AIDS-related non-Hodgkin lymphoma. Ann Oncol. 2015;26(5):958\u201366.","journal-title":"Ann Oncol"},{"issue":"21","key":"973_CR17","doi-asserted-by":"publisher","first-page":"3948","DOI":"10.1200\/JCO.2003.06.013","volume":"21","author":"C Simonelli","year":"2003","unstructured":"Simonelli C, Spina M, Cinelli R, Talamini R, Tedeschi R, Gloghini A, et al. Clinical features and outcome of primary effusion lymphoma in HIV-infected patients: a single-institution study. J Clin Oncol. 2003;21(21):3948\u201354.","journal-title":"J Clin Oncol"},{"issue":"9","key":"973_CR18","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1056\/NEJMoa1506816","volume":"373","author":"Group, I.S.S","year":"2015","unstructured":"Group, I.S.S, et al. Initiation of antiretroviral therapy in early asymptomatic HIV infection. N Engl J Med. 2015;373(9):795\u2013807.","journal-title":"N Engl J Med"},{"issue":"3","key":"973_CR19","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1159\/000458443","volume":"40","author":"T Welz","year":"2017","unstructured":"Welz T, Wyen C, Hensel M. Drug interactions in the treatment of malignancy in HIV-infected patients. Oncol Res Treat. 2017;40(3):120\u20137.","journal-title":"Oncol Res Treat"},{"issue":"10","key":"973_CR20","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1038\/s41409-019-0480-x","volume":"54","author":"K Hubel","year":"2019","unstructured":". Hubel K, et al. Autologous stem cell transplantation for HIV-associated lymphoma in the antiretroviral and rituximab era: a retrospective study by the EBMT Lymphoma Working Party. Bone Marrow Transplant. 2019;54(10):1625\u201331 Largest study so far evaluating the role of autologous stem cell transplantation in HIV-lymphoma.","journal-title":"Bone Marrow Transplant"},{"issue":"9","key":"973_CR21","doi-asserted-by":"publisher","first-page":"2943","DOI":"10.1182\/blood-2004-05-1747","volume":"104","author":"M Bower","year":"2004","unstructured":"Bower M, McCall-Peat N, Ryan N, Davies L, Young AM, Gupta S, et al. Protease inhibitors potentiate chemotherapy-induced neutropenia. Blood. 2004;104(9):2943\u20136.","journal-title":"Blood"},{"issue":"4","key":"973_CR22","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1093\/jac\/dki050","volume":"55","author":"M Cruciani","year":"2005","unstructured":"Cruciani M, Gatti G, Vaccher E, di Gennaro G, Cinelli R, Bassetti M, et al. Pharmacokinetic interaction between chemotherapy for non-Hodgkin's lymphoma and protease inhibitors in HIV-1-infected patients. J Antimicrob Chemother. 2005;55(4):546\u20139.","journal-title":"J Antimicrob Chemother"},{"issue":"27","key":"973_CR23","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","volume":"32","author":"BD Cheson","year":"2014","unstructured":"Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32(27):3059\u201368.","journal-title":"J Clin Oncol"},{"issue":"7","key":"973_CR24","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1097\/01.aids.0000222070.52996.76","volume":"20","author":"D Brust","year":"2006","unstructured":"Brust D, Polis M, Davey R, Hahn B, Bacharach S, Whatley M, et al. Fluorodeoxyglucose imaging in healthy subjects with HIV infection: impact of disease stage and therapy on pattern of nodal activation. AIDS. 2006;20(7):985\u201393.","journal-title":"AIDS"},{"issue":"15","key":"973_CR25","doi-asserted-by":"publisher","first-page":"3017","DOI":"10.1182\/blood-2009-11-253039","volume":"115","author":"K Dunleavy","year":"2010","unstructured":"Dunleavy K, Little RF, Pittaluga S, Grant N, Wayne AS, Carrasquillo JA, et al. The role of tumor histogenesis, FDG-PET, and short-course EPOCH with dose-dense rituximab (SC-EPOCH-RR) in HIV-associated diffuse large B-cell lymphoma. Blood. 2010;115(15):3017\u201324.","journal-title":"Blood"},{"issue":"10","key":"973_CR26","first-page":"3755","volume":"89","author":"G Gaidano","year":"1997","unstructured":"Gaidano G, et al. Frequent mutation of the 5\u2032 noncoding region of the BCL-6 gene in acquired immunodeficiency syndrome-related non-Hodgkin's lymphomas. Blood. 1997;89(10):3755\u201362.","journal-title":"Blood"},{"issue":"18","key":"973_CR27","doi-asserted-by":"publisher","first-page":"2285","DOI":"10.1097\/QAD.0b013e328010ac5b","volume":"20","author":"P Vaghefi","year":"2006","unstructured":"Vaghefi P, Martin A, Pr\u00e9vot S, Charlotte F, Camilleri-Bro\u00ebt S, Barli E, et al. Genomic imbalances in AIDS-related lymphomas: relation with tumoral Epstein-Barr virus status. AIDS. 2006;20(18):2285\u201391.","journal-title":"AIDS"},{"issue":"4","key":"973_CR28","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1097\/QAD.0b013e32834f30fa","volume":"26","author":"C Wyen","year":"2012","unstructured":"Wyen C, Jensen B, Hentrich M, Siehl J, Sabranski M, Esser S, et al. Treatment of AIDS-related lymphomas: rituximab is beneficial even in severely immunosuppressed patients. AIDS. 2012;26(4):457\u201364.","journal-title":"AIDS"},{"issue":"5","key":"973_CR29","doi-asserted-by":"publisher","first-page":"1538","DOI":"10.1182\/blood-2005-04-1437","volume":"106","author":"LD Kaplan","year":"2005","unstructured":"Kaplan LD, Lee JY, Ambinder RF, Sparano JA, Cesarman E, Chadburn A, et al. Rituximab does not improve clinical outcome in a randomized phase 3 trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin lymphoma: AIDS-malignancies consortium trial 010. Blood. 2005;106(5):1538\u201343.","journal-title":"Blood"},{"issue":"21","key":"973_CR30","doi-asserted-by":"publisher","first-page":"1790","DOI":"10.1200\/JCO.18.01994","volume":"37","author":"NL Bartlett","year":"2019","unstructured":". Bartlett NL, et al. Dose-Adjusted EPOCH-R Compared With R-CHOP as Frontline Therapy for Diffuse Large B-Cell Lymphoma: Clinical Outcomes of the Phase III Intergroup Trial Alliance\/CALGB 50303. J Clin Oncol. 2019;37(21):1790\u20139 Landmark trial showing that E-EPOCH is not superior to CHOP.","journal-title":"J Clin Oncol"},{"issue":"12","key":"973_CR31","doi-asserted-by":"publisher","first-page":"4653","DOI":"10.1182\/blood-2002-11-3589","volume":"101","author":"RF Little","year":"2003","unstructured":"Little RF, Pittaluga S, Grant N, Steinberg SM, Kavlick MF, Mitsuya H, et al. Highly effective treatment of acquired immunodeficiency syndrome-related lymphoma with dose-adjusted EPOCH: impact of antiretroviral therapy suspension and tumor biology. Blood. 2003;101(12):4653\u20139.","journal-title":"Blood"},{"issue":"8","key":"973_CR32","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1200\/JCO.2004.08.195","volume":"22","author":"JA Sparano","year":"2004","unstructured":"Sparano JA, Lee S, Chen MG, Nazeer T, Einzig A, Ambinder RF, et al. Phase II trial of infusional cyclophosphamide, doxorubicin, and etoposide in patients with HIV-associated non-Hodgkin's lymphoma: an eastern cooperative oncology group trial (E1494). J Clin Oncol. 2004;22(8):1491\u2013500.","journal-title":"J Clin Oncol"},{"issue":"7","key":"973_CR33","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1002\/cncr.21759","volume":"106","author":"R Weiss","year":"2006","unstructured":"Weiss R, Mitrou P, Arasteh K, Schuermann D, Hentrich M, Duehrsen U, et al. Acquired immunodeficiency syndrome-related lymphoma: simultaneous treatment with combined cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy and highly active antiretroviral therapy is safe and improves survival--results of the German multicenter trial. Cancer. 2006;106(7):1560\u20138.","journal-title":"Cancer"},{"issue":"5","key":"973_CR34","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.1182\/blood-2004-08-3300","volume":"105","author":"M Spina","year":"2005","unstructured":"Spina M, Jaeger U, Sparano JA, Talamini R, Simonelli C, Michieli M, et al. Rituximab plus infusional cyclophosphamide, doxorubicin, and etoposide in HIV-associated non-Hodgkin lymphoma: pooled results from 3 phase 2 trials. Blood. 2005;105(5):1891\u20137.","journal-title":"Blood"},{"issue":"25","key":"973_CR35","doi-asserted-by":"publisher","first-page":"4123","DOI":"10.1200\/JCO.2005.05.4684","volume":"24","author":"F Boue","year":"2006","unstructured":"Boue F, et al. Phase II trial of CHOP plus rituximab in patients with HIV-associated non-Hodgkin's lymphoma. J Clin Oncol. 2006;24(25):4123\u20138.","journal-title":"J Clin Oncol"},{"issue":"4","key":"973_CR36","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1111\/j.1365-2141.2007.06943.x","volume":"140","author":"JM Ribera","year":"2008","unstructured":"Ribera JM, Oriol A, Morgades M, Gonz\u00e1lez-Barca E, Miralles P, L\u00f3pez-Guillermo A, et al. Safety and efficacy of cyclophosphamide, adriamycin, vincristine, prednisone and rituximab in patients with human immunodeficiency virus-associated diffuse large B-cell lymphoma: results of a phase II trial. Br J Haematol. 2008;140(4):411\u20139.","journal-title":"Br J Haematol"},{"issue":"15","key":"973_CR37","doi-asserted-by":"publisher","first-page":"3008","DOI":"10.1182\/blood-2009-08-231613","volume":"115","author":"JA Sparano","year":"2010","unstructured":"Sparano JA, Lee JY, Kaplan LD, Levine AM, Ramos JC, Ambinder RF, et al. Rituximab plus concurrent infusional EPOCH chemotherapy is highly effective in HIV-associated B-cell non-Hodgkin lymphoma. Blood. 2010;115(15):3008\u201316.","journal-title":"Blood"},{"issue":"6769","key":"973_CR38","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/35000501","volume":"403","author":"AA Alizadeh","year":"2000","unstructured":"Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000;403(6769):503\u201311.","journal-title":"Nature"},{"issue":"30","key":"973_CR39","doi-asserted-by":"publisher","first-page":"5039","DOI":"10.1200\/JCO.2008.20.5450","volume":"27","author":"A Chadburn","year":"2009","unstructured":"Chadburn A, Chiu A, Lee JY, Chen X, Hyjek E, Banham AH, et al. Immunophenotypic analysis of AIDS-related diffuse large B-cell lymphoma and clinical implications in patients from AIDS malignancies consortium clinical trials 010 and 034. J Clin Oncol. 2009;27(30):5039\u201348.","journal-title":"J Clin Oncol"},{"issue":"26","key":"973_CR40","doi-asserted-by":"publisher","first-page":"3150","DOI":"10.1200\/JCO.2015.65.6520","volume":"34","author":"N Schmitz","year":"2016","unstructured":"Schmitz N, Zeynalova S, Nickelsen M, Kansara R, Villa D, Sehn LH, et al. CNS international prognostic index: a risk model for CNS relapse in patients with diffuse large B-cell lymphoma treated with R-CHOP. J Clin Oncol. 2016;34(26):3150\u20136.","journal-title":"J Clin Oncol"},{"issue":"18","key":"973_CR41","doi-asserted-by":"publisher","first-page":"4283","DOI":"10.1002\/cncr.25278","volume":"116","author":"JS Abramson","year":"2010","unstructured":"Abramson JS, Hellmann M, Barnes JA, Hammerman P, Toomey C, Takvorian T, et al. Intravenous methotrexate as central nervous system (CNS) prophylaxis is associated with a low risk of CNS recurrence in high-risk patients with diffuse large B-cell lymphoma. Cancer. 2010;116(18):4283\u201390.","journal-title":"Cancer"},{"issue":"5","key":"973_CR42","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1016\/j.humpath.2009.10.027","volume":"41","author":"A Carbone","year":"2010","unstructured":"Carbone A, Gloghini A, Aiello A, Testi A, Cabras A. B-cell lymphomas with features intermediate between distinct pathologic entities. From pathogenesis to pathology. Hum Pathol. 2010;41(5):621\u201331.","journal-title":"Hum Pathol"},{"issue":"5","key":"973_CR43","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.1002\/cncr.10365","volume":"94","author":"J Cortes","year":"2002","unstructured":"Cortes J, Thomas D, Rios A, Koller C, O'Brien S, Jeha S, et al. Hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone and highly active antiretroviral therapy for patients with acquired immunodeficiency syndrome-related Burkitt lymphoma\/leukemia. Cancer. 2002;94(5):1492\u20139.","journal-title":"Cancer"},{"issue":"6","key":"973_CR44","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1002\/cncr.11628","volume":"98","author":"ES Wang","year":"2003","unstructured":"Wang ES, Straus DJ, Teruya-Feldstein J, Qin J, Portlock C, Moskowitz C, et al. Intensive chemotherapy with cyclophosphamide, doxorubicin, high-dose methotrexate\/ifosfamide, etoposide, and high-dose cytarabine (CODOX-M\/IVAC) for human immunodeficiency virus-associated Burkitt lymphoma. Cancer. 2003;98(6):1196\u2013205.","journal-title":"Cancer"},{"issue":"8","key":"973_CR45","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1093\/annonc\/mdq677","volume":"22","author":"JA Barnes","year":"2011","unstructured":"Barnes JA, LaCasce AS, Feng Y, Toomey CE, Neuberg D, Michaelson JS, et al. Evaluation of the addition of rituximab to CODOX-M\/IVAC for Burkitt\u2019s lymphoma: a retrospective analysis. Ann Oncol. 2011;22(8):1859\u201364.","journal-title":"Ann Oncol"},{"issue":"2","key":"973_CR46","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1182\/blood.V87.2.495.bloodjournal872495","volume":"87","author":"D Hoelzer","year":"1996","unstructured":"Hoelzer D, Ludwig WD, Thiel E, Gassmann W, L\u00f6ffler H, Fonatsch C, et al. Improved outcome in adult B-cell acute lymphoblastic leukemia. Blood. 1996;87(2):495\u2013508.","journal-title":"Blood"},{"issue":"10","key":"973_CR47","doi-asserted-by":"publisher","first-page":"2341","DOI":"10.3109\/10428194.2013.878933","volume":"55","author":"B Xicoy","year":"2014","unstructured":"Xicoy B, Ribera JM, M\u00fcller M, Garc\u00eda O, Hoffmann C, Oriol A, et al. Dose-intensive chemotherapy including rituximab is highly effective but toxic in human immunodeficiency virus-infected patients with Burkitt lymphoma\/leukemia: parallel study of 81 patients. Leuk Lymphoma. 2014;55(10):2341\u20138.","journal-title":"Leuk Lymphoma"},{"issue":"20","key":"973_CR48","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1056\/NEJMoa1308392","volume":"369","author":"K Dunleavy","year":"2013","unstructured":"Dunleavy K, Pittaluga S, Shovlin M, Steinberg SM, Cole D, Grant C, et al. Low-intensity therapy in adults with Burkitt's lymphoma. N Engl J Med. 2013;369(20):1915\u201325.","journal-title":"N Engl J Med"},{"issue":"Suppl 1","key":"973_CR49","first-page":"188","volume":"130","author":"M Roschewski","year":"2017","unstructured":". Roschewski M, et al. Risk-adapted therapy in adults with Burkitt lymphoma: Results of NCI 9177, a multicenter prospective phase II study of DA-EPOCH-R. Blood. 2017;130(Suppl 1):188 DA-EPOCH-R may be effective in HIV-Burkitt\u2019s lymphoma and better tolerated compared to more intensive regimens.","journal-title":"Blood"},{"issue":"4","key":"973_CR50","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1182\/blood.V89.4.1413","volume":"89","author":"HJ Delecluse","year":"1997","unstructured":"Delecluse HJ, Anagnostopoulos I, Dallenbach F, Hummel M, Marafioti T, Schneider U, et al. Plasmablastic lymphomas of the oral cavity: a new entity associated with the human immunodeficiency virus infection. Blood. 1997;89(4):1413\u201320.","journal-title":"Blood"},{"issue":"5","key":"973_CR51","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1097\/QAD.0b013e32835e069d","volume":"27","author":"P Schommers","year":"2013","unstructured":"Schommers P, Wyen C, Hentrich M, Gillor D, Zoufaly A, Jensen B, et al. Poor outcome of HIV-infected patients with plasmablastic lymphoma: results from the German AIDS-related lymphoma cohort study. AIDS. 2013;27(5):842\u20135.","journal-title":"AIDS"},{"issue":"4","key":"973_CR52","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1093\/annonc\/mdw684","volume":"28","author":"E Tchernonog","year":"2017","unstructured":". Tchernonog E, et al. Clinical characteristics and prognostic factors of plasmablastic lymphoma patients: analysis of 135 patients from the LYSA group. Ann Oncol. 2017;28(4):843\u20138 Large trial from the French group summarizing important information on plasmablastic lymphoma.","journal-title":"Ann Oncol"},{"issue":"3","key":"973_CR53","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1111\/bjh.13300","volume":"169","author":"JJ Castillo","year":"2015","unstructured":"Castillo JJ, Reagan JL, Sikov WM, Winer ES. Bortezomib in combination with infusional dose-adjusted EPOCH for the treatment of plasmablastic lymphoma. Br J Haematol. 2015;169(3):352\u20135.","journal-title":"Br J Haematol"},{"issue":"3","key":"973_CR54","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1159\/000504608","volume":"43","author":"K Ando","year":"2020","unstructured":"Ando K, Imaizumi Y, Kobayashi Y, Niino D, Hourai M, Sato S, et al. Bortezomib- and Lenalidomide-based treatment of refractory plasmablastic lymphoma. Oncol Res Treat. 2020;43(3):112\u20136.","journal-title":"Oncol Res Treat"},{"issue":"15","key":"973_CR55","doi-asserted-by":"publisher","first-page":"2323","DOI":"10.1182\/blood-2014-10-567479","volume":"125","author":"JJ Castillo","year":"2015","unstructured":"Castillo JJ, Bibas M, Miranda RN. The biology and treatment of plasmablastic lymphoma. Blood. 2015;125(15):2323\u201330.","journal-title":"Blood"},{"issue":"Suppl 1","key":"973_CR56","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1182\/blood-2019-129702","volume":"134","author":"CR Tan","year":"2019","unstructured":"Tan CR, Barta SK, Lensing SY, Noy A. A multicenter, open-label feasibility study of daratumumab with dose-adjusted EPOCH in newly diagnosed plasmablastic lymphoma: AIDS malignancy consortium 105. Blood. 2019;134(Suppl 1):1595.","journal-title":"Blood"},{"issue":"10","key":"973_CR57","doi-asserted-by":"publisher","first-page":"4115","DOI":"10.1182\/blood-2002-10-3090","volume":"101","author":"U Klein","year":"2003","unstructured":"Klein U, Gloghini A, Gaidano G, Chadburn A, Cesarman E, Dalla-Favera R, et al. Gene expression profile analysis of AIDS-related primary effusion lymphoma (PEL) suggests a plasmablastic derivation and identifies PEL-specific transcripts. Blood. 2003;101(10):4115\u201321.","journal-title":"Blood"},{"issue":"19","key":"973_CR58","doi-asserted-by":"publisher","first-page":"4372","DOI":"10.1200\/JCO.2005.07.084","volume":"23","author":"E Boulanger","year":"2005","unstructured":"Boulanger E, G\u00e9rard L, Gabarre J, Molina JM, Rapp C, Abino JF, et al. Prognostic factors and outcome of human herpesvirus 8-associated primary effusion lymphoma in patients with AIDS. J Clin Oncol. 2005;23(19):4372\u201380.","journal-title":"J Clin Oncol"},{"issue":"5","key":"973_CR59","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1634\/theoncologist.12-5-569","volume":"12","author":"YB Chen","year":"2007","unstructured":"Chen YB, Rahemtullah A, Hochberg E. Primary effusion lymphoma. Oncologist. 2007;12(5):569\u201376.","journal-title":"Oncologist"},{"issue":"2","key":"973_CR60","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1002\/ajh.24251","volume":"91","author":"S Guillet","year":"2016","unstructured":"Guillet S, G\u00e9rard L, Meignin V, Agbalika F, Cuccini W, Denis B, et al. Classic and extracavitary primary effusion lymphoma in 51 HIV-infected patients from a single institution. Am J Hematol. 2016;91(2):233\u20137.","journal-title":"Am J Hematol"},{"issue":"12","key":"973_CR61","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1093\/annonc\/mdl139","volume":"17","author":"TR Halfdanarson","year":"2006","unstructured":"Halfdanarson TR, Markovic SN, Kalokhe U, Luppi M. A non-chemotherapy treatment of a primary effusion lymphoma: durable remission after intracavitary cidofovir in HIV negative PEL refractory to chemotherapy. Ann Oncol. 2006;17(12):1849\u201350.","journal-title":"Ann Oncol"},{"issue":"5","key":"973_CR62","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1111\/ejh.12174","volume":"91","author":"M Ozbalak","year":"2013","unstructured":"Ozbalak M, Tokatl\u0131 I, \u00d6zdemirli M, Tecimer T, Ar MC, \u00d6rnek S, et al. Is valganciclovir really effective in primary effusion lymphoma: case report of an HIV(\u2212) EBV(\u2212) HHV8(+) patient. Eur J Haematol. 2013;91(5):467\u20139.","journal-title":"Eur J Haematol"},{"issue":"1","key":"973_CR63","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1093\/neuonc\/now155","volume":"19","author":"NK Gupta","year":"2017","unstructured":"Gupta NK, Nolan A, Omuro A, Reid EG, Wang CC, Mannis G, et al. Long-term survival in AIDS-related primary central nervous system lymphoma. Neuro-Oncology. 2017;19(1):99\u2013108.","journal-title":"Neuro-Oncology"},{"issue":"5","key":"973_CR64","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1097\/QAD.0b013e3283437f77","volume":"25","author":"CJ Achenbach","year":"2011","unstructured":"Achenbach CJ, Cole SR, Kitahata MM, Casper C, Willig JH, Mugavero MJ, et al. Mortality after cancer diagnosis in HIV-infected individuals treated with antiretroviral therapy. AIDS. 2011;25(5):691\u2013700.","journal-title":"AIDS"},{"issue":"3","key":"973_CR65","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1097\/QAD.0000000000000030","volume":"28","author":"TS Uldrick","year":"2014","unstructured":"Uldrick TS, Pipkin S, Scheer S, Hessol NA. Factors associated with survival among patients with AIDS-related primary central nervous system lymphoma. AIDS. 2014;28(3):397\u2013405.","journal-title":"AIDS"},{"issue":"6","key":"973_CR66","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1200\/JCO.2008.19.6626","volume":"27","author":"T Powles","year":"2009","unstructured":"Powles T, Robinson D, Stebbing J, Shamash J, Nelson M, Gazzard B, et al. Highly active antiretroviral therapy and the incidence of non-AIDS-defining cancers in people with HIV infection. J Clin Oncol. 2009;27(6):884\u201390.","journal-title":"J Clin Oncol"},{"issue":"4","key":"973_CR67","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1111\/hiv.12200","volume":"16","author":"C Hoffmann","year":"2015","unstructured":"Hoffmann C, Hentrich M, Gillor D, Behrens G, Jensen B, Stoehr A, et al. Hodgkin lymphoma is as common as non-Hodgkin lymphoma in HIV-positive patients with sustained viral suppression and limited immune deficiency: a prospective cohort study. HIV Med. 2015;16(4):261\u20134.","journal-title":"HIV Med"},{"issue":"5","key":"973_CR68","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1097\/QAD.0000000000000980","volume":"30","author":"C Hoffmann","year":"2016","unstructured":"Hoffmann C, Schommers P, Wolf E, M\u00fcller M, Schultze A, Krznaric I, et al. CD4+ and CD8+ T-cell kinetics in aviremic HIV-infected patients developing Hodgkin or non-Hodgkin lymphoma. AIDS. 2016;30(5):753\u201360.","journal-title":"AIDS"},{"issue":"5","key":"973_CR69","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000149","volume":"2","author":"DA Eichenauer","year":"2018","unstructured":"Eichenauer DA, Andr\u00e9 M, Johnson P, Fossa A, Casasnovas O, Engert A. Controversies in the treatment of classical Hodgkin lymphoma. Hemasphere. 2018;2(5):e149.","journal-title":"Hemasphere"},{"issue":"33","key":"973_CR70","doi-asserted-by":"publisher","first-page":"4117","DOI":"10.1200\/JCO.2012.41.8137","volume":"30","author":"M Hentrich","year":"2012","unstructured":"Hentrich M, Berger M, Wyen C, Siehl J, Rockstroh JK, M\u00fcller M, et al. Stage-adapted treatment of HIV-associated Hodgkin lymphoma: results of a prospective multicenter study. J Clin Oncol. 2012;30(33):4117\u201323.","journal-title":"J Clin Oncol"},{"issue":"Suppl 1","key":"973_CR71","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1182\/blood-2019-126787","volume":"134","author":"PG Rubinstein","year":"2019","unstructured":"Rubinstein PG, Moore PC, Bimali M, Chadburn A, Cesarman E, Rudek M, et al. Safety and efficacy of brentuximab vedotin in combination with AVD in stage II-IV HIV-associated classical Hodgkin lymphoma: results of the phase II study, AMC 085. Blood. 2019;134(Suppl 1):130.","journal-title":"Blood"},{"issue":"7","key":"973_CR72","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1016\/j.bbmt.2009.03.023","volume":"15","author":"V Gupta","year":"2009","unstructured":"Gupta V, Tomblyn M, Pedersen TL, Atkins HL, Battiwalla M, Gress RE, et al. Allogeneic hematopoietic cell transplantation in human immunodeficiency virus-positive patients with hematologic disorders: a report from the center for international blood and marrow transplant research. Biol Blood Marrow Transplant. 2009;15(7):864\u201371.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"973_CR73","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.bbmt.2015.08.006","volume":"22","author":"C Johnston","year":"2016","unstructured":"Johnston C, Harrington R, Jain R, Schiffer J, Kiem HP, Woolfrey A. Safety and efficacy of combination antiretroviral therapy in human immunodeficiency virus-infected adults undergoing autologous or allogeneic hematopoietic cell transplantation for hematologic malignancies. Biol Blood Marrow Transplant. 2016;22(1):149\u201356.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"973_CR74","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000018","volume":"2","author":"J Buechner","year":"2018","unstructured":"Buechner J, Kersten MJ, Fuchs M, Salmon F, J\u00e4ger U. Chimeric antigen receptor-T cell therapy: practical considerations for implementation in Europe. Hemasphere. 2018;2(1):e18.","journal-title":"Hemasphere"},{"issue":"21","key":"973_CR75","doi-asserted-by":"publisher","first-page":"3692","DOI":"10.1002\/cncr.32411","volume":"125","author":"JS Abramson","year":"2019","unstructured":"Abramson JS, Irwin KE, Frigault MJ, Dietrich J, McGree B, Jordan JT, et al. Successful anti-CD19 CAR T-cell therapy in HIV-infected patients with refractory high-grade B-cell lymphoma. Cancer. 2019;125(21):3692\u20138.","journal-title":"Cancer"}],"updated-by":[{"DOI":"10.1007\/s11912-021-01112-z","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2021,8,9]],"date-time":"2021-08-09T00:00:00Z","timestamp":1628467200000}}],"container-title":["Current Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-020-00973-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11912-020-00973-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-020-00973-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,14]],"date-time":"2021-08-14T23:14:39Z","timestamp":1628982879000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11912-020-00973-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,15]]},"references-count":75,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["973"],"URL":"https:\/\/doi.org\/10.1007\/s11912-020-00973-0","relation":{},"ISSN":["1523-3790","1534-6269"],"issn-type":[{"value":"1523-3790","type":"print"},{"value":"1534-6269","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,15]]},"assertion":[{"value":"15 August 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 August 2021","order":2,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":3,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":4,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s11912-021-01112-z","URL":"https:\/\/doi.org\/10.1007\/s11912-021-01112-z","order":5,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The author declares that there is no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by the author.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}],"article-number":"111"}}